European consensus-based interdisciplinary guideline for diagnosis and treatment of basal cell carcinoma-update 2023

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11120%2F23%3A43925961" target="_blank" >RIV/00216208:11120/23:43925961 - isvavai.cz</a>

Result on the web

<a href="https://doi.org/10.1016/j.ejca.2023.113254" target="_blank" >https://doi.org/10.1016/j.ejca.2023.113254</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.ejca.2023.113254" target="_blank" >10.1016/j.ejca.2023.113254</a>

Result language

angličtina

Original language name

European consensus-based interdisciplinary guideline for diagnosis and treatment of basal cell carcinoma-update 2023

Original language description

Basal cell carcinoma (BCC) is the most common malignant tumour in white populations. Multidisciplinary experts from European Association of Dermato-Oncology (EADO), European Dermatology Forum, European Society for Radiotherapy and Oncology (ESTRO), Union Européenne des Médecins Spécialistes, and the European Academy of Dermatology and Venereology developed updated recommendations on diagnosis and treatment of BCC. BCCs were categorised into &apos;easy-to-treat&apos; (common) and &apos;difficult-to-treat&apos; according to the new EADO clinical classification. Diagnosis is based on clinico-dermatoscopic features, although histopathological confirmation is mandatory in equivocal lesions. The first-line treatment of BCC is complete surgery. Micrographically controlled surgery shall be offered in high-risk and recurrent BCC, and BCC located on critical anatomical sites. Topical therapies and destructive approaches can be considered in patients with low-risk superficial BCC. Photodynamic therapy is an effective treatment for superficial and low-risk nodular BCCs. Management of &apos;difficult-to-treat&apos; BCCs should be discussed by a multidisciplinary tumour board. Hedgehog inhibitors (HHIs), vismodegib or sonidegib, should be offered to patients with locally advanced and metastatic BCC. Immunotherapy with anti-PD1 antibodies (cemiplimab) is a second-line treatment in patients with a progression of disease, contraindication, or intolerance to HHI therapy. Radiotherapy represents a valid alternative in patients who are not candidates for or decline surgery, especially elderly patients. Electrochemotherapy may be offered when surgery or radiotherapy is contraindicated. In Gorlin patients, regular skin examinations are required to diagnose and treat BCCs at an early stage. Long-term follow-up is recommended in patients with high-risk BCC, multiple BCCs, and Gorlin syndrome.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30204 - Oncology

Project

—

Continuities

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Publication year

2023

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

European Journal of Cancer

ISSN

0959-8049

e-ISSN

1879-0852

Volume of the periodical

192

Issue of the periodical within the volume

October

Country of publishing house

GB - UNITED KINGDOM

Number of pages

37

Pages from-to

113254

UT code for WoS article

001071184500001

EID of the result in the Scopus database

2-s2.0-85168105665